NASDAQ$DAWN
Day One Biopharmaceuticals Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Day One reported second quarter financial results and corporate progress.
Day One Biopharmaceuticals announced its second quarter 2023 financial results, highlighting the initiation of the rolling submission of the tovorafenib NDA and updated data from the FIREFLY-1 trial presented at ASCO. A public offering was completed, raising $172.5 million and extending the cash runway into 2026.
- Initiated rolling submission of the tovorafenib New Drug Application (NDA) in relapsed or progressive pediatric low-grade glioma (pLGG) in May 2023.
- Reported FIREFLY-1 trial results with an overall response rate (ORR) of 67% and a clinical benefit rate (CBR) of 93% in RANO-HGG evaluable patients.
- Completed a $172.5 million public offering, strengthening the balance sheet and extending cash runway into 2026.
- Cash, cash equivalents and short-term investments totaled $442.9 million on June 30, 2023.
Headline financials
Revenue & EPS history
Day One · Revenue · Quarterly
$52.8M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
-1.4%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+1.2%
Avg return
30 days after
45%
9 / 20 earnings
Positive
+23.6%
Q2 2022
Best reaction
-16.6%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -9.2% | -13.9% | +78.0% | |
| Q3 2025 | +0.0% | +3.7% | +34.8% | |
| Q2 2025 | -15.4% | -14.2% | +9.7% | |
| Q1 2025 | -9.6% | -5.9% | +2.9% | |
| Q4 2024 | -16.5% | -30.2% | -31.7% | |
| Q3 2024 | +2.6% | +3.2% | -2.9% | |
| Q2 2024 | -6.8% | -9.4% | -11.0% | |
| Q1 2024 | -0.5% | -6.8% | -23.9% | |
| Q4 2023 | +14.5% | +15.0% | +4.0% | |
| Q3 2023 | -3.1% | -11.1% | -3.7% | |
| Q2 2023 | +1.3% | +4.3% | +9.6% | |
| Q1 2023 | +12.7% | +10.3% | +7.3% | |
| Q4 2022 | +5.3% | -4.2% | -32.8% | |
| Q3 2022 | +2.7% | +10.6% | +14.3% | |
| Q2 2022 | +23.6% | +18.9% | +24.4% | |
| Q1 2022 | +8.5% | +21.8% | -6.1% | |
| Q4 2021 | +3.7% | -3.8% | -6.9% | |
| Q3 2021 | -9.2% | -15.7% | -31.7% | |
| Q2 2021 | -16.6% | -7.6% | -5.2% | |
| Q4 2020 | -16.6% | -7.6% | -5.2% | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro